Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 145.00
Bid: 130.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 30.00 (23.077%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON AIM WINNERS & LOSERS: CPPGroup Earnings To Beat Forecasts

Mon, 18th Jan 2021 10:41

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday.

----------

AIM WINNERS

----------

CPPGroup, up 46% at 478.00 pence. The insurance and financial services company said earnings for 2020 are expected to surpass market consensus, with the firm expecting 2020 earnings before interest, tax, depreciation, and amortization of between GBP7.1 million to GBP7.3 million, ahead of market forecasts of GBP6.4 million.

----------

Faron Pharmaceuticals, up 22% at 337.56 pence. The biopharmaceutical said the US Department of Defense has chosen the HIBISCUS Study to receive USD6.1 million of funding from the Coronavirus Aid, Relief & Economic Security Act. The phase II/III HIBISCUS trial will assess Traumakine, Faron's IV IFN beta-1a, for the treatment of hospitalised Covid-19 patients in the US.

----------

Mosman Oil & Gas, up 22% at 0.214 pence. The Australia and US-focused oil and gas explorer confirmed the completion of the sale of the Welch Project, in Texas, for USD420,000.

----------

Augean, up 10% at 206.25 pence. The waste management company said it expects to report an adjusted pretax profit for 2020 at least in line with the year before, despite the decline of its North Sea business and the ongoing Covid-19 pandemic. In 2019, Augean's adjusted pretax profit was GBP19.2 million.

----------

AIM LOSERS

----------

Velocys, down 26% at 7.64 pence. The sustainable fuels technology company said Shell International Petroleum has withdrawn from the Altalto Joint Development agreement. Velocys and British Airways will continue to work to secure finance for the Altalto Immingham plant, and will continue talks with potential finance sources.

----------

SEC Newgate, down 12% at 42.50 pence. The public relations firm said its two largest UK agencies, SEC Newgate UK - Newgate Communications - and Newington Communications, will merge and rebrand as SEC Newgate UK. As part of this, SEC Newgate will increase its stake in Newington to 100% from 60%, paying GBP420,799 for the 40% minority stake it did not already own.

----------

Remote Monitored Systems, down 8.7% at 2.74 pence. The data collection and surveying firm said the last test for its 4-ply mask, the biocompatibility test, has been delayed and is now expected to be completed in the next week. The mask manufacturing machine arrived from Lemu, as expected, and has been installed in Nottingham's BioCity, with work beginning this week to commission the machine and commence production.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
14 Mar 2022 14:14

IN BRIEF: Faron research sheds light on Covid-linked mutations

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Publishes research expanding on analysis of a gene mutation in an interferon receptor that is linked to corticosteroid response and outcomes in acute respiratory distress syndrome and Covid-19 patients. Builds on Faron's findings from its phase III 'Interest' trial for Traumakine in ARDS patients. Traumakine is an investigational intravenous interferon beta-1a therapy.

Read more
4 Mar 2022 20:53

TRADING UPDATES: IOG to cut Gazprom ties; wholesale changes at Donegal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News:

Read more
23 Feb 2022 20:11

TRADING UPDATES: BiVictriX expands development; Okyo wins US patent

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
23 Feb 2022 13:37

Faron upbeat on updated data from cancer treatment study

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced updated survival data from the phase 1 and 2 study investigating the safety and efficacy of 'bexmarilimab' on Wednesday.

Read more
31 Jan 2022 14:49

EXECUTIVE CHANGES: Anglo Pacific promotes investment head to CEO

EXECUTIVE CHANGES: Anglo Pacific promotes investment head to CEO

Read more
4 Jan 2022 16:10

Marie-Louise Fjallskog tapped as Faron's new chief medical officer

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced the appointment of Marie-Louise Fjällskog as its chief medical officer on Tuesday, to be based in Boston, Massachusetts and effective immediately.

Read more
4 Jan 2022 15:54

Faron appoints Sensei Biotherapeutics's Marie-Louise Fjallskog as CMO

Faron appoints Sensei Biotherapeutics's Marie-Louise Fjallskog as CMO

Read more
1 Dec 2021 15:59

EXECUTIVE CHANGES: GCP Infrastructure picks Rothschild banker as chair

EXECUTIVE CHANGES: GCP Infrastructure picks Rothschild banker as chair

Read more
9 Nov 2021 22:01

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

Read more
9 Nov 2021 11:23

Faron Pharmaceuticals wins dispute with Rentschler at tribunal

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Tuesday that the arbitration tribunal appointed by the Arbitration Institute of the Stockholm Chamber of Commerce (SCC) had ruled in its favour in its case against Rentschler Biopharma.

Read more
1 Oct 2021 11:45

IN BRIEF: Faron Pharma raises EUR10.5 million in share placing

IN BRIEF: Faron Pharma raises EUR10.5 million in share placing

Read more
30 Sep 2021 18:06

IN BRIEF: Faron Pharma to raise at least EUR8 million via placing

IN BRIEF: Faron Pharma to raise at least EUR8 million via placing

Read more
17 Sep 2021 17:52

IN BRIEF: Faron Pharma hails updated results from Matins study

IN BRIEF: Faron Pharma hails updated results from Matins study

Read more
26 Aug 2021 14:56

TRADING UPDATES: Glenveagh, IOG swing to profit; Faron loss widens

TRADING UPDATES: Glenveagh, IOG swing to profit; Faron loss widens

Read more
25 Aug 2021 11:43

Faron doses first patient in Covid-19 treatment trial

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals announced on Wednesday that the first patient has been dosed in the phase 2 and 3 'HIBISCUS' trial, assessing 'Traumakine', or intravenous interferon beta-1a, as a first-line treatment for hospitalised Covid-19 patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.